MOTS-c: the exercise signal written into your mitochondria

Your body makes a molecule during exercise that does some of the work of exercise. It’s called MOTS-c, and it comes from a strange place — not the main genome in the nucleus, but the tiny separate one inside your mitochondria, the engines that turn food into usable energy in every cell you have.

Here’s the part worth slowing down for. The amount of it circulating in your blood falls as you get older. And when researchers gave it back to old animals, some of what age had taken came back with it. If that holds up in people, MOTS-c isn’t a supplement story. It’s a story about handing your cells back an instruction they stop sending on their own.

What it could actually do for you

Start with the one that matters most day to day: fuel. In the lab, MOTS-c makes muscle better at pulling sugar out of the blood and burning it — the same thing that goes right when you’re fit and lean, and the same thing that drifts wrong through your forties. The 2015 discovery paper from Lee and colleagues in Cell Metabolism showed obese mice given MOTS-c put on less fat and handled sugar like leaner animals. In plain terms: it nudged their metabolism back toward the younger setting.

Then strength and stamina. Reynolds and colleagues, in Nature Communications in 2021, took old mice, gave them MOTS-c, and watched grip strength and treadmill endurance climb. The peptide switched on the same repair-and-adapt programmes inside the cell that a hard session switches on in a young body. That’s the finding behind the label the internet loves: exercise in a vial.

Put those two together and you can see why longevity circles won’t stop talking about it. A single signal that helps you carry fuel like a leaner man and hold onto strength like a younger one is about as close to the whole longevity wish list as one molecule gets. That’s the upside, and it’s a genuinely exciting one.

Why the biology is worth the excitement

Most of the peptides your body runs on are written into your nuclear DNA — the big genome people mean when they say your genome. MOTS-c isn’t. It’s spelled out inside the mitochondrial genome, the little loop of DNA in the cell’s engine room that biology textbooks spent decades treating as an afterthought.

That’s what makes this more interesting than the average compound. MOTS-c leaves the mitochondria, travels through the blood, and acts like a hormone — a message from your engines to the rest of the body about how hard they’re working and what to do about it. It’s a genuinely new kind of signal, only pinned down in 2015, and your own body already speaks its language. The idea more or less writes itself: give it back as the level drops, in the exact form your cells already know how to read.

The honest boundary

Here’s the clarity, because hope is only worth having if it survives it.

Almost everything above happened in a mouse. Mouse-recovers-grip-strength and you-recover-grip-strength are different sentences, and the distance between them is the whole caveat. There’s no published trial of anyone injecting MOTS-c and measuring what it does — not for strength, not for fat, not for anything the marketing implies.

The human record so far comes in two thin slices. Most of it is observational: a 2022 review in the International Journal of Molecular Sciences gathers what biology has measured without dosing anyone, and the pattern is consistent — circulating MOTS-c runs lower in older people, and lower again in people carrying obesity and metabolic trouble. That tells you MOTS-c is wrapped up in the things you care about. It doesn’t tell you that injecting it moves them.

The other slice is one small trial, and it’s honest about its own limits. In late 2025, Elhusseiny and colleagues put nineteen active men through a stretch of calf immobilisation, randomised to repeated heat exposure or a sham. The heat raised circulating MOTS-c (p=0.033); the sham didn’t. It’s a real human study — randomised, in healthy men — and the thing that moved the peptide was heat, not a needle. What it proves is that this pathway can be pushed in a living person. What it doesn’t touch is whether giving someone the peptide does anything at all.

So the honest position is hope with your eyes open. The mechanism is real and unusually clean for this corner of the market. The human proof is one heat-stress trial and a stack of associations. The study that would actually settle it — give middle-aged adults MOTS-c, measure their body composition, blood sugar and strength against placebo — simply hasn’t been run. If it turns out as good as the animal work hints, it could be a serious tool. That if is the whole game.

Where the regulators sit

This part is moving faster than the trials. MOTS-c is on the FDA Pharmacy Compounding Advisory Committee docket for the July 23, 2026 session, listed for evaluation under obesity and osteoporosis — not longevity, not the exercise-mimic pitch. The committee is being asked a narrow question: whether US pharmacies should be able to compound MOTS-c for those specific medical uses. What a review like that actually decides is a longer story, told in what a PCAC review actually is. The short version: a committee vote is a recommendation, not an approval, and MOTS-c is not an approved drug today.

Anti-doping is simpler. MOTS-c isn’t named on the current WADA prohibited list — but its whole metabolic-and-endurance profile is exactly the activity class WADA watches, so if you compete, check the code on the day rather than trusting this line.

What happens next

The mechanism is real. The proof isn’t finished. And the version of MOTS-c worth being excited about looks nothing like a vial mailed from a research-chemical site, with contents nobody has assayed and a dose scaled off a rodent.

It looks like a physician writing a prescription against a real indication, a US-licensed pharmacy compounding it, and a test on every batch before it ships. That legitimate version is what we’re building at Wolverine Health — and it can’t open until the regulation does, which is the honest reason it hasn’t yet. The date circled on the wall is that July 23 PCAC session. Leave your email and we’ll tell you what the vote does to legal access the day it lands.